...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>AIDS Research and Human Retroviruses >Long-term efficacy and safety of Atazanavir/Ritonavir treatment in a real-life cohort of treatment-experienced patients with HIV type 1 infection
【24h】

Long-term efficacy and safety of Atazanavir/Ritonavir treatment in a real-life cohort of treatment-experienced patients with HIV type 1 infection

机译：Atazanavir / Ritonavir治疗在具有治疗经验的HIV 1型感染患者的真实队列中的长期疗效和安全性

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Atazanavir-based regimens have established efficacy and safety in both antiretroviral (ARV)-naive and -experienced patients. However, data evaluating effectiveness beyond 2 years is sparse. Therefore, we assessed the long-term outcomes of ritonavir-boosted atazanavir (ATV/r)-containing regimens in ARV-experienced patients in a clinical setting in a noncomparative, retrospective, observational study collecting data from three European HIV databases on ARV-experienced adults with HIV-1 infection starting an ATV/r-based regimen. Data were extracted every 6 months (maximum follow-up 5 years). Primary outcome was the proportion of patients remaining on ATV/r by baseline HIV-1 RNA (<500 or ≥500 copies/ml). Secondary outcomes included time to virologic failure, reasons for discontinuation, and long-term safety profile. The duration of treatment and time to virologic failure were analyzed using the Kaplan-Meier method. Data were analyzed for 1,294 ARV-experienced patients (male 74%; mean ART exposure 5.7 years). After 3 years, 56% (95% CI: 52%, 60%) of patients with baseline HIV-1 RNA <500 copies/ml and 53% (95% CI: 49%, 58%) of those with HIV-1 RNA ≥500 copies/ml remained on ATV/r. After 3 years, 75% (95% CI: 69%, 80%) of patients with baseline HIV-1 RNA <50 copies/ml remained suppressed and 51% (95% CI: 47%, 55%) of those with baseline HIV-1 RNA ≥50 copies/ml achieved and maintained virologic suppression. Although adverse events (AEs) were the main known reason for discontinuation, no unexpected AEs were observed. In a real-life setting ATV/r-based regimens demonstrated sustained virologic suppression in ARV-experienced patients. After long-term therapy the majority of patients remained on treatment and no unexpected AEs were observed.
机译：基于Atazanavir的方案已在初次使用抗逆转录病毒（ARV）和有经验的患者中确立了疗效和安全性。但是，超过2年的评估效果的数据很少。因此，我们在一项非对照，回顾性观察性研究中，从三个欧洲艾滋病毒数据库中收集了有关抗逆转录病毒治疗经验的数据，评估了利妥那韦增强的阿扎那韦（ATV / r）方案在抗逆转录病毒治疗经验的患者中的长期结果成人患有HIV-1感染，开始采用基于ATV / r的治疗方案。每6个月提取一次数据（最长随访5年）。主要结局是通过基线HIV-1 RNA（<500或≥500拷贝/ ml）保留在ATV / r上的患者比例。次要结果包括病毒感染失败的时间，停药原因和长期安全性。使用Kaplan-Meier方法分析治疗的持续时间和病毒学衰竭时间。分析了1,294名有ARV经验的患者（男性74％;平均ART暴露5.7年）的数据。 3年后，基线HIV-1 RNA <500拷贝/ ml的患者中有56％（95％CI：52％，60％）和HIV-1的53％（95％CI：49％，58％） RNA≥500拷贝/ ml保留在ATV / r上。 3年后，基线HIV-1 RNA <50拷贝/毫升的患者中有75％（95％CI：69％，80％）仍然受到抑制，基线水平的患者中有51％（95％CI：47％，55％） HIV-1 RNA≥50拷贝/ ml，并保持病毒学抑制作用。尽管不良事件（AEs）是停药的主要已知原因，但未观察到意外的AEs。在现实生活中，基于ATV / r的治疗方案在经历过ARV的患者中显示出持续的病毒学抑制作用。长期治疗后，大多数患者仍在接受治疗，未观察到意外的不良事件。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号